

DESCRIPTION

Source	Chinese Hamster Ovary cell line, CHO-derived human IL-10 R beta protein		
	Human IL-10 R β (Met20-Ser220) Accession # Q08334.2	GGIEGRMD	Human IgG ₁ (Pro100-Lys330)
	N-terminus		C-terminus
N-terminal Sequence Analysis	Met20		
Structure / Form	Disulfide-linked homodimer		
Predicted Molecular Mass	50 kDa		

SPECIFICATIONS


SDS-PAGE	72-82 kDa, under reducing conditions.
Activity	Measured by its binding ability in a functional ELISA. Recombinant Human IL-10 R β Fc Chimera (Catalog # 11460-RB) binds Recombinant Human IL-28 R α /IFN- λ R1 Fc Chimera (Catalog # 5260-MR) in the presence of Recombinant Human IL-28B/IFN- λ 3 (Catalog # 5259-IL/CF) with an ED ₅₀ of 0.250-3.00 μ g/mL.
Endotoxin Level	<0.10 EU per 1 μ g of the protein by the LAL method.
Purity	>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
Formulation	Lyophilized from a 0.2 μ m filtered solution in PBS. See Certificate of Analysis for details.

PREPARATION AND STORAGE

Reconstitution	Reconstitute at 500 μ g/mL in PBS.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. <ul style="list-style-type: none"> • 12 months from date of receipt, -20 to -70 °C as supplied. • 1 month, 2 to 8 °C under sterile conditions after reconstitution. • 3 months, -20 to -70 °C under sterile conditions after reconstitution.


DATA

Binding Activity



Recombinant Human IL-10 R β Fc Chimera Protein Binding Activity. Recombinant Human IL-10 R β Fc Chimera Protein (Catalog # 11460-RB) binds Recombinant Human IL-28 R α /IFN- λ R1 Fc Chimera (Catalog # 5260-MR) in the presence of Recombinant Human IL-28B/IFN- λ 3 (Catalog # 5259-IL/CF) with an ED₅₀ of 0.250-3.00 μ g/mL.

SDS-PAGE



Recombinant Human IL-10 R β Fc Chimera Protein SDS-PAGE. 2 μ g/lane of Recombinant Human IL-10 R β Fc Chimera Protein (Catalog # 11460-RB) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 72-82 kDa and 140-165 kDa, respectively.

BACKGROUND

Interleukin-10 Receptor beta (IL-10 R β), also known as IL-10 R2 and CRF2-4, is a 60 kDa transmembrane glycoprotein that functions as a co-receptor for several class 2 cytokines including Interleukins-10, -22, -26, -28A/IFN- λ 2, -28B/IFN- λ 3, and -29/IFN- λ (1, 2). IL-10 R β associates with ligand-specific receptor subunits to form signaling receptor complexes, e.g. IL-10 R α for IL-10 (3, 4), IL-20 R α for IL-26 (5, 6), IL-22 R α for IL-22 (7, 8), and IL-28 R α for IL-28A, IL-28B, and IL-29 (9, 10). IL-10 R β is widely expressed, while the associated receptor subunits exhibit differential expression patterns (1). The ligand-specific subunits are responsible for the divergent functions of these cytokines, encompassing immune suppression, promotion or inhibition of inflammation, mucosal defense, antiviral immunity, and hematopoiesis (1). IL-10 R β deficient mice lack responsiveness to each of those cytokines. IL-10 R β contributes to ligand binding, but effective signaling is only triggered in the presence of the ligand-specific subunit (8, 9, 11). In the case of IL-10, a cytokine dimer binds to two IL-10 R α /IL-10R1 chains, resulting in recruitment of two IL-10 R β /IL-10R2 chains (3, 12). Some members of the IL-10 family are monomeric cytokines and interact with single molecules of IL-10 R β and their ligand-specific subunit (1). Mature human IL-10 R β consists of a 201 amino acid (aa) extracellular region with two fibronectin type-III domains, a 22 aa transmembrane segment and a 83 aa cytoplasmic domain (13). Within the ECD, human IL-10 R β shares 75% and 78% aa sequence identity with mouse and rat IL-10 R β , respectively.

References:

1. Commins, S. *et al.* (2008) J. Allergy Clin. Immunol. **121**:1108.
2. Pestka, S. *et al.* (2004) Annu. Rev. Immunol. **22**:929.
3. Kotenko, S.V. *et al.* (1997) EMBO J. **16**:5894.
4. Spencer, S.D. *et al.* (1998) J. Exp. Med. **187**:571.
5. Sheikh, F. *et al.* (2004) J. Immunol. **172**:2006.
6. Hor, S. *et al.* (2004) J. Biol. Chem. **279**:33343.
7. Kotenko, S.V. *et al.* (2000) J. Biol. Chem. **276**:2725.
8. Xie, M.-H. *et al.* (2000) J. Biol. Chem. **275**:31335.
9. Kotenko, S.V. *et al.* (2003) Nat. Immunol. **4**:69.
10. Sheppard, P. *et al.* (2003) Nat. Immunol. **4**:63.
11. Yoon, S.I. *et al.* (2006) J. Biol. Chem. **281**:35088.
12. Pletnev, S. *et al.* (2005) BMC Struct. Biol. **5**:10.
13. Lutfalla, G. *et al.* (1993) Genomics **16**:366.